16 results about "Exocrine secretion" patented technology

This invention relates to a method for producing chondroitin with improved safety and extracellular secretion levels, belonging to the field of genetic engineering. Using the probiotic *Escherichia coli* Nissle 1917 as the host, this invention designs methods to increase chondroitin production by studying the chondroitin synthase KfoAC and the chondroitin-linking Kdo synthase. The relationship between chondroitin synthesis and secretion in *E. coli* was clarified, and the specificity of the chondroitin-linking Kdo was investigated, resulting in an extracellular chondroitin production of 0.32 g / L. Subsequently, the introduction of the protein KfoB from the chondroitin synthesis gene cluster increased the extracellular chondroitin production to 0.51 g / L. Further screening and optimization of the expression of transport proteins resulted in an extracellular chondroitin production of 0.73 g / L in shake flasks. Further optimization using a 7-L fermenter resulted in an extracellular chondroitin production of 5.9 g / L.

According to the pancreas exocrine function in-vivo high-resolution monitoring system and monitoring method provided by the invention, exciting light emitted by a laser module (1) is reflected by a scanning galvanometer (21) and then is transmitted through a dichroscope (22); the femtosecond pulse exciting light passing through the dichroscope (22) is focused on a pancreas sample arranged on the objective table (24) by the objective lens (23) and excites a tryptophan two-photon fluorescence signal in the pancreas sample, and the tryptophan two-photon fluorescence signal is collected by the objective lens (23); after being reflected by the dichroscope (22), the femtosecond pulse exciting light is separated from the femtosecond pulse exciting light and then detected by the detector (25), so that a two-photon fluorescence image of tryptophan in the pancreatic sample is obtained, and tryptophan two-photon fluorescence can display pancreatic adenosine zymogen particles. The tryptophan two-photon fluorescence signal is used for carrying out delayed dynamic imaging on a pancreas sample, so that in-vivo, three-dimensional and high-resolution characterization of the pancreas zymogen particle number, distribution polarity, movement tendency and other characteristics can be reflected, and the pancreas exocrine function of the organism can be reflected in real time.

FIELD: veterinary medicine and dietetics.SUBSTANCE: development of complete feed compositions that can provide a therapeutic effect in cases of exocrine pancreatic insufficiency. The composition of a complete dietary feed for cats with exocrine pancreatic insufficiency has been developed in the following ratio, wt.%: grain part: mixture of rice, wheat, hulled barley and corn – 37.0; protein part of plant origin: isolated soy protein, beet pulp, wheat bran, flax seeds – 22.0; protein part of animal origin: feather meal, chicken liver, egg powder – 25.0; mineral supplement: feed chalk, monocalcium phosphate, table salt, plantain seeds Plantago psyllium, mannanoligasaccharides with beta-glucans and lutein – 2.0; vitamin premix: A, D3, E, K, B1, B2, B3, B5, B6, B12, Bc, H, taurine, inulin, beech lignocellulose, complex of natural fulvic and humic acids – 2.5; flavor enhancer in the form of enzymatic hydrolysate of pork and chicken by-products – 3–3.5; brewer's yeast – 2.5–3.0; a mixture of fish and chicken fat – 5.0–6.0.EFFECT: obtaining food for cats with exocrine pancreatic insufficiency, which is easily reproducible, clinically effective, and convenient in dosing and use.1 cl, 3 tbl, 1 ex

The separation and detection method comprises the following steps: rinsing placenta or villus tissues in a PBS (Phosphate Buffer Solution) added with a 1% penicillin-streptomycin double antibody solution, digesting the placenta or villus tissues into single cells by using a 1640 culture medium containing I-type and IV-type collagenase after the placenta or villus tissues are rinsed sufficiently to obtain a cell suspension, and culturing the cell suspension for later use; diluting and neutralizing collagenase digestive juice by using a 1640 culture medium containing high-temperature heat-inactivated fetal calf serum according to 5 times of volume; repeatedly discarding the precipitate, recovering the supernatant, and centrifuging to obtain a coarse migration body; and establishing a density gradient by using Optiprep as a density medium, washing the precipitate with PBS, and centrifuging to obtain the trophoblast cell-derived transporter. The invention provides a group of placenta villus trophoblast cell source migration body specific expression membrane proteins for the first time, and provides a method for specifically capturing the placenta trophoblast source migration body on the basis of the placenta villus trophoblast cell source migration body specific expression membrane proteins, so that a new direction for researching a trophoblast dysfunction related disease mechanism can be enriched.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

The present patent application discloses a kind of recombinant collagen VII and its preparation method and use.The recombinant collagen VII is obtained by multiple repetitions of short amino acid sequence GLPGAKGEKGAP.The secretory yield of the recombinant collagen VII in commercialized pichia expression system can be as high as about 17.3g / L, the extracellular secreted protein is basically not degraded during fermentation process, and more than 90% purity can be achieved by simple ultrafiltration and decolorization, industrial production can be realized;Moreover, the recombinant collagen VII has more optimal biological activities of promoting autophagy, improving endoplasmic reticulum stress state, promoting collagen secretion and inhibiting matrix metalloproteinase degradation of collagen, and shows good firming and anti-wrinkle effects.

This invention relates to bifunctional compounds and the use of such bifunctional compounds to reduce plasma levels of extracellular target molecules via lysosomal degradation. These bifunctional compounds have cell surface receptor ligands covalently linked to ligands capable of binding to extracellular target molecules (such as growth factors, cytokines, chemokines, hormones, neurotransmitters, capsids, soluble receptors, extracellular secretory proteins, antibodies, lipoproteins, exosomes, viruses, cell or plasma membrane proteins), wherein said cell surface receptors are associated with receptor-mediated endocytosis, including lysosomal degradation mediated by desialylate glycoprotein receptor (ASGPR) and lysosomal degradation mediated by mannose-6-phosphate receptor (M6PR). Pharmaceutical compositions comprising such bifunctional compounds and methods of treating diseases or disorders mediated by extracellular molecules using such bifunctional compounds are also provided herein.

This invention relates to the field of vaccine technology and provides a CHO cell line for exocrine expression of PEDV GIIb subtype S protein and its application. The CHO cell line integrates a codon-optimized PEDV GIIb S protein encoding gene carrying the TPA signal peptide into its chromosome. The nucleotide sequence of the PEDV GIIb S protein encoding gene is shown in SEQ ID NO.1. This invention uses currently prevalent GIIb strains as the antigen source to ensure vaccine strain matching; it constructs a secretory expression structure, thereby significantly improving the exocrine expression efficiency of the S protein; it precisely truncates the transmembrane region while retaining key structural domains, maintaining the protein's native conformation and immunogenicity; and it obtains a CHO cell line with stable gene integration and long-term passage to maintain expression levels through optimized transfection conditions and an antibiotic selection system.

This invention relates to the fields of microbial fermentation and genetic engineering technology, specifically disclosing a method for preparing human type III collagen fragments. Based on Pichia pastoris, this invention constructs a multidimensional synergistic expression system of "molecular chaperone co-expression - precursor supply - osmotic pressure adaptation regulation," reducing the structural instability of collagen fragments during secretion and post-processing, and constructing an expression system suitable for stable and efficient secretion of collagen fragments. The method described in this invention can achieve efficient extracellular secretory expression of human type III collagen fragments, and the obtained protein has high structural uniformity and stability, with a protein yield of up to 6.55 g / L under 5 L fermenter conditions. The method described in this invention is suitable for the large-scale preparation of human type III collagen fragments and provides a new technical solution for obtaining collagen products with high structural uniformity and good functional activity.

In the field of medical device technology, we provide a pusher for nasal sprays for the exocrine system. [Solution] The device includes a drug solution bottle, a pressing component, an atomizing chamber 5, a microporous screen plate 6, and a nozzle component 7. The atomizing chamber is provided with a flow guide cone and an annular buffer chamber for guiding the drug solution and buffering the flow velocity. The microporous screen plate has uniformly distributed micropores and atomizes the drug solution into droplets with concentrated particle size. The nozzle component includes a throttling ring and an opening for restricting the initial spray velocity of the droplets and for ejecting them at an inclined angle. The coordination of these structures reduces the shear force generated on the exocrine system during the spraying process, improving consistency and dose reproducibility in the administration of exocrine nasal sprays. Conventional nasal spray devices are prone to structural damage during the spraying process for shear-sensitive substances such as exocrine systems, resulting in insufficient consistency and reproducibility of administration.

The invention relates to the technical field of screening and application of probiotics, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving inflammation and application of the bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis). The strain is separated from infant excrement, has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.34159, is acid-resistant and cholate-resistant, and has outstanding antibacterial and anti-inflammatory regulation capabilities. The strain can secrete an approximately circular or elliptical vesicle structure outside a cell. The vesicles can significantly inhibit lipopolysaccharide-induced macrophage M1 type polarization, regulate inflammatory factor balance and pancreatic function indexes, significantly improve pathological injuries of mice with acute pancreatitis, and have broad application prospects.

This invention relates to the field of vaccine technology and provides a CHO cell line for the TGEV strain S protein and its application. The CHO cell line has a TGEV S protein encoding gene with codon optimization carrying the TPA signal peptide integrated into its chromosome. The nucleotide sequence of the TGEV S protein encoding gene is shown in SEQ ID NO.1. This invention not only significantly improves the exocrine expression efficiency and stability of the TGEV S protein but also increases protein quantity and yield, establishing an expression system that can operate stably for a long time and is suitable for large-scale production, demonstrating clear technological advancement and practical application value.

The invention discloses a plasmid for simultaneously realizing display and secretion, application of the plasmid, a system capable of simultaneously realizing display and secretion and a construction method of the system. The plasmid for realizing cell surface display and cell exocrine comprises a first FC protein coding region and a second FC protein coding region, the first FC protein coding region comprises a first signal peptide, a first FC protein region and an MCS region, the MCS region is used for accessing a target gene, and the second FC protein coding region comprises a second signal peptide, a second FC protein region and a transmembrane domain TM. By utilizing the dimer form of the FC fusion protein, on one hand, the antibody or the functional protein can be expressed on the cell surface, and on the other hand, the corresponding antibody molecule or the functional protein can be secreted in the culture supernatant at the same time.

The present invention discloses a process for the secretion of brazzein in improved yield.

The present disclosure provides an extracellular secretion that is useful in the treatment of various diseases. In one embodiment, the present disclosure provides an extracellular secretion including approximately 6×1010 / mL or more small extracellular vesicles (sEVs). In one embodiment, the present disclosure provides an extracellular secretion including small extracellular vesicles (sEVs) having a particle size distribution in which the particle size mode is approximately 100 nm to approximately 120 nm. In one embodiment, the extracellular secretion is obtained from a culture supernatant of mesenchymal stem cells. In one embodiment, the extracellular secretion is used to treat aging.

The invention belongs to the technical field of food or medicine, and particularly relates to a buccal tablet and a preparation method thereof. The buccal tablet comprises a first supporting layer, a functional layer and a second supporting layer which are sequentially laminated, wherein the functional layer comprises an active substance, and the first supporting layer and the second supporting layer are both exocrine dissolving layers. The supporting layer in the buccal tablet is the exocrine dissolving layer and has a dissolving characteristic in saliva, so that the problem that the buccal tablet needs to be spitted after oral administration is solved, and the supporting layer also has an edible characteristic, so that discomfort and harm cannot be generated after unintentional swallowing.